Motexafin gadolinium: Gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-tex, GdT2B2, PCI 0120

Drugs in R and D

Volumn 5, Issue 1, 2004, Pages 52-57

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM TEXAPHYRIN;

APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BRAIN METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FECES COLOR; GLIOBLASTOMA; HEMOLYTIC ANEMIA; HUMAN; KIDNEY FAILURE; LIVER DYSFUNCTION; LUNG CANCER; LYMPHOMA; MOUSE; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NONHUMAN; PONS ANGLE TUMOR; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISCOLORATION; SKIN DISEASE; URINE COLOR;

ANIMALS; DRUGS, INVESTIGATIONAL; HUMANS; METALLOPORPHYRINS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 1042281012     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405010-00012     Document Type: Article

References (18)

1. Pharmacyclics Inc. Pharmacyclics' Xcytrin Clinical Trial Results Highlighted at ASCO 'Clinical Problems In Oncology' Sessions. Media Release: 4 Jun 2003, Available from URL: http://www.pcyc.com
2. Pharmacyclics Inc. Pharmacyclics Announces Start of Phase 3 SMART Trial of Xcytrin in Non-Small Cell Lung Cancer Patients with Brain Metastases. Media Release: 19 Dec 2002. Available from URL: http://www.pcyc.com
3. Pharmacyclics Inc. Pharmacyclics Announces Publication of Phase 3 Study of Xcytrin For Brain Metastases, Media Release: 26 Jun 2003. Available from URL: http://www.pcyc.com
4. Pharmacyclics Inc. Pharmacyclics Reports Fourth Quarter and Fiscal 2003 Financial Results. Media Release: 21 Aug 2003. Available from URL: http://www.pcyc.com
5. Carde P. Pong S, Haie Ch. A phase IB/II multi-dose trial of gadolinium-texaphyrin, a radiation sensitizer detectable by MR imaging in patients with brain metastases: preliminary results of response and survival. Eighth International Congress on Anti-Cancer Treatment: 114, 3 Feb 1998
6. Rosenthal DI, Nurenberg P, Becerra CR. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clinical Cancer Research 5: 739-745, Apr 1999
7. Miller RA, Woodburn K, Fan Q, et al. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. International Journal of Radiation Oncology Biology Physics 45: 981-989, No. 4, 1999
8. Bernhard EJ, Mitchell JB, Deen D, et al. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent. Cancer Research 60: 86-91, 1 Jan 2000
9. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to lonizing radiation by forming reactive oxygen species. 37th Annual Meeting of the American Society of Clinical Oncology 20: 259, Part 1, 12 May 2001
10. Pharmacyclics Inc, Pharmacyclics Reports Data Highlighting Novel Mechanism and Diverse Potential Uses of Xcytrin in Cancer, Including Multiple Myeloma. Media Release: 11 Apr 2003. Available From URL: http://www.pcyc.com
11. Pharmacyclics Inc. Pharmacyclics announces Gd-Tex results at American Society of Therapeutic Radiology and Oncology meeting. Media Release: [3 pages], 28 Oct 1998
12. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. Journal of Clinical Oncology 19: 2074-2083, 1 Apr 2001
13. Pharmacyclics Inc. Pharmacyclics reports results from lead-in phase of ongoing phase III clinical trial of Xcytrin for brain metastases. Media Release: [2 pages], 1 Nov 1999. Available from URL: http://www.pcyc.com
14. Pharmacyclics Inc. Pharmacyclics announces results of phase III clinical trial of Xcytrin in brain metastases. Media Release: [4 pages], 13 Dec 2001. Available from URL: http://www.pharmacyclics.com
15. Pharmacyclics Inc. Pharmacyclics announces phase III clinical trial results indicate Xcytrin improves neurologic function in lung cancer patients with brain metastases. Media Release: [3 pages], 8 Jan 2002. Available from URL: http://www,pcyc.com
16. Pharmacyclics Inc. Pharmacyclics Announces Complete Results From Xcytrin Phase 3 Clinical Trial Presented at 44th Annual ASTRO Meeting. Media Release: 8 Oct 2002. Available from URL: http://www.pcyc.com
17. Pharmacyclics Inc. Pharmacyclics Announces Interim Results From Xcytrin Phase 2 Clinical Trial In Primary Brain Tumors. Media Release: 9 Oct 2002. Available from URL: http://www.pcyc.com
18. Viala J, Vanel D, Meingan E. Magnetic resonance imaging of brain metastases with gadolinium-texaphyrin (Gd-Tex): preliminary results. Eighth International Congress on Anti-Cancer Treatment: 218, 3 Feb 1998